Claims
- 1. A process for preparing a pharmaceutical formulation containing two or more active pharmaceutical ingredients comprising:
(a) contacting two or more active pharmaceutical ingredients with a supercritical fluid to form a supercritical fluid solution; and (b) separating the active ingredients from the supercritical fluid solution to yield a powder precipitate.
- 2. The process according to claim 1, wherein the supercritical fluid is carbon dioxide.
- 3. The process according to claim 2, wherein at least one of the active pharmaceutical ingredients is an anti-infective agent.
- 4. The process according to claim 3, wherein the anti-infective ingredient is selected from the group consisting of macrolide antibiotics, anthracycline antibiotics, quinolone antibiotics, cephalosporins, β-lactam antibiotics, penicillins, aminoglycosides, and sulfonamides.
- 5. The process according to claim 2, wherein the active pharmaceutical ingredients are a combination of two anti-infective agents.
- 6. The process according to claim 5, wherein the combination of two anti-infective agents are selected from the group consisting of ampicillin sodium/sulbactam sodium, ticarcillin disodium/clavulanate potassium, quinupristin/dalfopristin, piperacillin sodium/tazobactam sodium, and imipenem/cilastatin.
- 7. The process according to claim 2, wherein at least one of the active pharmaceutical ingredients is an anticancer agent.
- 8. The process according to claim 7, wherein the anticancer agent is selected from the group consisting of etoposide, paclitaxel, altretamine, cisplatin, sarcolysine, alkylating agents, bleomycin, busulfan, docetaxel, carboplatin, doxorubicin, vincristine, fluorouracil, methotrexate, vinorelbine, cyclophosphamide/, ifosfarnide, mesna, gemcitabine hydrochloride, irinotecan hydrochloride, 5-fluorouracil, platinoids, and vinorelbine tartarate.
- 9. The process according to claim 2, wherein the active pharmaceutical ingredients are a combination of two anticancer agents.
- 10. The process according to claim 9, wherein the combination of two anticancer agents are selected from the group consisting of etoposide/paclitaxel, altretamine/cisplatin; altretamine/sarcolysine, altretamine/alkylating agents, bleomycin/cisplatin, busulfan/docetaxel, busulfan/carboplatin, cisplatin/doxorubicin, cisplatin/vincristine, cisplatin/fluorouracil, cisplatin/methotrexate, cisplatin/vinorelbine, cyclophosphamide/etoposide, etoposide/ifosfamide, ifosfamide/mesna, gemcitabine hydrochloride/cisplatin, gemcitabine/paclitaxel, irinotecan hydrochloride/5-fluorouracil, paclitaxel/platinoids, vinorelbine tartarate/platinoids, vinorelabine tartrate/paclitaxel, paclitaxel/cisplatin, and toposide/cisplatin.
- 11. The process according to claim 2, wherein the active ingredients are separated from the supercritical carbon dioxide solution by spraying the solution through a nozzle and recovering the precipitate.
- 12. The process according to claim 11, wherein the active pharmaceutical ingredients are contacted a solvent prior to step (a).
- 13. The process according to claim 11, wherein the supercritical fluid is contacted with a solvent prior to step (a).
- 14. A process of preparing a pharmaceutical formulation containing a combination of active pharmaceutical ingredients selected from the group consisting of two anti-infective agents and two anticancer agents comprising:
(a) contacting the two pharmaceutical ingredients with supercritical carbon dioxide to form a supercritical carbon dioxide solution; (b) spraying the supercritical carbon dioxide solution through a nozzle; and (c) recovering the precipitate in a powder form containing the combination of active pharmaceutical agents.
- 15. The process according to claim 14, wherein the combination of active pharmaceutical ingredients is a combination of anti-infective agents selected from the group consisting of ampicillin sodium/sulbactam sodium, ticarcillin disodium/clavulanate potassium, quinupristin/dalfopristin, piperacillin sodium/tazobactam sodium, and imipenem/cilastatin.
- 16. The process according to claim 14, wherein the combination of active pharmaceutical ingredients is a combination of anticancer agents selected from the group consisting of etoposide/paclitaxel, altretamine/cisplatin; altretamine/sarcolysine, altretamine/alkylating agents, bleomycin/cisplatin, busulfan/docetaxel, busulfan/carboplatin, cisplatin/doxorubicin, cisplatin/vincristine, cisplatin/fluorouracil, cisplatin/methotrexate, cisplatin/vinorelbine, cyclophosphamide/etoposide, etoposide/ifosfamide, ifosfamide/mesna, gemcitabine hydrochloride/cisplatin, gemcitabine/paclitaxel, irinotecan hydrochloride/5-fluorouracil, paclitaxel/platinoids, vinorelbine tartarate/platinoids, vinorelabine tartrate/paclitaxel, paclitaxel/cisplatin, and toposide/cisplatin.
- 17. A process for preparing a pharmaceutical formulation containing two or more active pharmaceutical ingredients comprising:
(a) combining two or more active ingredients with a solvent to form a solution; (b) contacting the solution with a supercritical fluid; and (c) recovering the precipitate in a powder form.
- 18. The process according to claim 17, wherein the supercritical fluid is carbon dioxide.
- 19. The process according to claim 18, wherein at least one of the active pharmaceutical ingredients is an anti-infective agent.
- 20. The process according to claim 19, wherein the anti-infective agent is selected from the group consisting of macrolide antibiotics, anthracycline antibiotics, quinolone antibiotics, cephalosporins, β-lactam antibiotics, penicillins, aminoglycosides, and sulfonamides.
- 21. The process according to claim 18, wherein two or more of the active pharmaceutical ingredients are a combination of two anti-infective agents.
- 22. The process according to claim 21, wherein the combination of two anti-infective active ingredients are selected from the group consisting of ampicillin sodium/sulbactam sodium, ticarcillin disodium/clavulanate potassium, quinupristin/dalfopristin, piperacillin sodium/tazobactam sodium, and imipenem/cilastatin.
- 23. The process according to claim 18, wherein the solution containing two or more active ingredients is contacted with the supercritical carbon dioxide by spraying the solution though a nozzle.
- 24. The process according to claim 18, wherein the solution containing two or more active ingredients is contacted with the supercritical carbon dioxide by pumping the supercritical carbon dioxide into the solution.
- 25. The process according to claim 18, wherein the supercritical carbon dioxide is contacted with a solvent prior to step (b).
- 26. A process for preparing a pharmaceutical formulation containing a combination of two active pharmaceutical ingredients selected from the group consisting of two anti-infective agents and two anticancer agents comprising anti-infective agents comprising:
(a) combining the two active pharmaceutical ingredients with a solvent to form a solution; (b) contacting the solution with supercritical carbon dioxide; and (c) recovering the precipitate in a powder form containing the combination of two active pharmaceutical ingredients.
- 27. The process according to claim 26, wherein the combination of two active pharmaceutical ingredients is a combination of two anti-infective agents selected from the group consisting of ampicillin sodium/sulbactam sodium, ticarcillin disodium/clavulanate potassium, quinupristin/dalfopristin, piperacillin sodium/tazobactam sodium, and imipenem/cilastatin.
- 28. The process according to claim 26, wherein the combination of active pharmaceutical ingredients is a combination of two anticancer agents selected from the group consisting of etoposide/paclitaxel, altretamine/cisplatin; altretamine/sarcolysine, altretamine/alkylating agents, bleomycin/cisplatin, busulfan/docetaxel, busulfan/carboplatin, cisplatin/doxorubicin, cisplatin/vincristine, cisplatin/fluorouracil, cisplatin/methotrexate, cisplatin/vinorelbine, cyclophosphamide/etoposide, etoposide/ifosfamide, ifosfamide/mesna, gemcitabine hydrochloride/cisplatin, gemcitabine/paclitaxel, irinotecan hydrochloride/5-fluorouracil, paclitaxel/platinoids, vinorelbine tartarate/platinoids, vinorelabine tartrate/paclitaxel, paclitaxel/cisplatin, and toposide/cisplatin.
- 29. The process according to claim 17, wherein the solution is contacted with a supercritical fluid by spraying the solution into a chamber containing the supercritical fluid.
- 30. The process according to claim 26, wherein the solution is contacted with a supercritical fluid by spraying the solution into a chamber containing the supercritical fluid.
- 31. A supercritical fluid solution comprising a supercritical fluid and two or more active pharmaceutical ingredients.
- 32. The supercritical fluid solution according to claim 31, wherein the supercritical fluid is supercritical carbon dioxide.
- 33. The supercritical fluid solution according to claim 32, wherein the solution contains two or more anti-infective active pharmaceutical ingredients.
- 34. The supercritical fluid solution according to claim 32, wherein the solution contains two or more anticancer active pharmaceutical ingredients.
- 35. The pharmaceutical formulation containing two or more active pharmaceutical ingredients selected from the group consisting of anti-infective agents and anticancer agents prepared by the process of claim 2.
- 36. A process for preparing a combination product containing two or more substances comprising:
(a) contacting two or more desired substances with a supercritical fluid to form a supercritical fluid solution; and (b) separating the substances from the supercritical fluid solution to yield a powder precipitate.
- 37. A process for preparing a combination product containing two or more substances comprising:
(a) combining two or more substances with a solvent to form a solution; (b) mixing the solution with a supercritical fluid; and (c) recovering the precipitate in a powder form.
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 60/435,054, filed Dec. 19, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60435054 |
Dec 2002 |
US |